Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

At-211-anti-CD45 radioimmunotherapy as conditioning prior to haploidentical hematopoietic cell transplantation in mouse models

View Full Paper
Ask AI
Bookmark
Share

Authors

DHDonald K. Hamlin

Discussion

Loading...

Member takes

Overview

Radioimmunotherapy improves donor chimerism in mice undergoing haploidentical transplantation, suggesting reduced toxicity without total body irradiation.

Key Points

  • To evaluate the efficacy of 211At-anti-CD45 radioimmunotherapy as a conditioning regimen before haploidentical hematopoietic cell transplantation.
  • Used B6SJLF1/J mice for transplantation experiments
  • Administered 211At-anti-CD45 or myeloablative total body irradiation
  • Combined treatment with varied doses of cyclophosphamide
  • Assessed donor-origin chimerism via multicolor flow cytometry at different time points
  • 211At-anti-CD45 RIT showed donor-origin chimerism levels similar to total body irradiation
  • Average chimerism at 28 days was 56.54% (B220) compared to 92.40% in TBI group
  • Chimerism levels persisted at 84 days with values approaching those of the TBI group
  • The study indicates that RIT with pre-CY can enhance engraftment while reducing toxicity

Cite This Study

Donald K. Hamlin (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6dfhttps://doi.org/10.1182/blood-2025-5866
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy2026 · 2 citations
  2. 2Total marrow irradiation-based, intensified reduced-intensity conditioning regimen for haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: A prospective study2025
  3. 3The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy2026 · 1 citations
  4. 4First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia2025
  5. 5Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality2025